moxifloxacin has been researched along with Body Weight in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Grosjean, P; Urien, S | 1 |
| Alteraz, H; Blau, H; Fabian, I; Horev-Azaria, L; Kariv, N; Kletter, Y; Shalit, I; Shechtman, I | 1 |
| Braun, J; Dirnagl, U; Halle, E; Megow, D; Meisel, A; Meisel, C; Prass, K; Victorov, I; Volk, HD; Wolf, T | 1 |
| Bishai, WR; Calamita, H; Ginsburg, AS; Grosset, JH; Scott, CP; Sun, R | 1 |
| Domdey-Bette, A; Henninger, K; Hucke, F; Kohlsdorfer, C; Siefert, HM; Stass, HH | 1 |
| Enzmann, HG; Iatropoulos, MJ; Jeffrey, AM; Schlueter, G; von Keutz, E; Williams, GM | 1 |
1 trial(s) available for moxifloxacin and Body Weight
| Article | Year |
|---|---|
Reevaluation of moxifloxacin pharmacokinetics and their direct effect on the QT interval.
Topics: Adolescent; Adult; Anti-Infective Agents; Arrhythmias, Cardiac; Aza Compounds; Body Composition; Body Weight; Electrocardiography; Female; Fluoroquinolones; Heart Rate; Humans; Male; Middle Aged; Models, Biological; Moxifloxacin; Quinolines; Tissue Distribution; Young Adult | 2012 |
5 other study(ies) available for moxifloxacin and Body Weight
| Article | Year |
|---|---|
Immunomodulatory and protective effects of moxifloxacin against Candida albicans-induced bronchopneumonia in mice injected with cyclophosphamide.
Topics: Animals; Anti-Infective Agents; Aza Compounds; Body Weight; Bronchopneumonia; Candidiasis; Ceftazidime; Cephalosporins; Cyclophosphamide; Cytokines; Fluoroquinolones; Lung; Male; Mice; Mice, Inbred BALB C; Moxifloxacin; Neutropenia; Protein Synthesis Inhibitors; Quinolines; Survival | 2002 |
Preventive antibacterial treatment improves the general medical and neurological outcome in a mouse model of stroke.
Topics: Animals; Antibiotic Prophylaxis; Aza Compounds; Bacterial Infections; Body Weight; Disease Models, Animal; Dose-Response Relationship, Drug; Escherichia coli Infections; Fever; Fluoroquinolones; Gram-Positive Bacterial Infections; Hypothermia; Immune Tolerance; Male; Mice; Mice, Inbred Strains; Moxifloxacin; Opportunistic Infections; Pneumonia, Bacterial; Quinolines; Sepsis; Stroke; Survival Rate; Treatment Outcome | 2004 |
Emergence of fluoroquinolone resistance in Mycobacterium tuberculosis during continuously dosed moxifloxacin monotherapy in a mouse model.
Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Body Weight; Diet; DNA Gyrase; DNA Primers; Drug Resistance, Bacterial; Eating; Female; Fluoroquinolones; Mice; Mice, Inbred BALB C; Moxifloxacin; Mycobacterium tuberculosis; Quinolines; Reverse Transcriptase Polymerase Chain Reaction; Tuberculosis | 2005 |
Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: a comparison in humans and other mammalian species.
Topics: Animals; Anti-Infective Agents; Area Under Curve; Aza Compounds; Body Weight; Dogs; Female; Fluoroquinolones; Humans; Macaca mulatta; Male; Mice; Moxifloxacin; Quinolines; Rats; Swine; Swine, Miniature | 1999 |
Assessment of chronic toxicity and carcinogenicity in an accelerated cancer bioassay in rats of moxifloxacin, a quinolone antibiotic.
Topics: Administration, Oral; Animals; Anti-Infective Agents; Aza Compounds; Body Weight; Carcinogenicity Tests; Carcinogens; Cocarcinogenesis; Female; Fluoroquinolones; Male; Moxifloxacin; Neoplasms, Experimental; Organ Size; Quinolines; Rats; Rats, Wistar; Time Factors | 2001 |